Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | ESR1 | P03372 | 2/20 | 0.55 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.54 |
| ▸ | LSS | P48449 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | PDE1A | P54750 | 1/20 | 0.49 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.49 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | THRA | P10827 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30721819 | 1.00 | KDM4E (0.56) | KDM4EALDH1A1SMN1; SMN2ESR1CHRNB2 | |
| SCHEMBL7222639 | 0.91 | CHRNB2 (0.65) | KDM4EALDH1A1SMN1; SMN2ESR1CHRNB2 | |
| SCHEMBL30628302 | 0.91 | CHRNB2 (0.65) | KDM4EALDH1A1SMN1; SMN2ESR1CHRNB2 | |
| SCHEMBL19553110 | 0.82 | KDM4E (0.56) | KDM4EALDH1A1SMN1; SMN2ESR1MAPT | |
| SCHEMBL11983542 | 0.81 | KDM4E (0.57) | KDM4EALDH1A1SMN1; SMN2ESR1CHRNB2 | |
| SCHEMBL4187873 | 0.80 | TSHR (0.54) | SMN1; SMN2KMT2ATHRB | |
| SCHEMBL22837826 | 0.79 | KDM4E (0.56) | KDM4EALDH1A1SMN1; SMN2ESR1CHRNB2 | |
| SCHEMBL1428483 | 0.79 | KDM4E (0.56) | KDM4EALDH1A1SMN1; SMN2ESR1CHRNB2 | |
| SCHEMBL188707 | 0.79 | TSHR (0.63) | KDM4EALDH1A1SMN1; SMN2ESR1CHRNB2 | |
| SCHEMBL2095959 | 0.79 | KDM4E (0.56) | KDM4EALDH1A1SMN1; SMN2ESR1CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030153604-A1 | Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds | AVENTIS PHARMACEUTICALS INC. | 2003-08-14 | — | — | US | disclosed |
| US-6541505-B1 | Inhibiting the activity of Factor Xa; treating a disease state associated with a physiologically detrimental excess amount of thrombin. | AVENTIS PHARMACEUTICALS INC. | 2003-04-01 | — | — | US | disclosed |
| CN-1333766-A | Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds as factor xainhibitors | AVENTIS PHARM PROD INC (US) | 2002-01-30 | — | — | CN | disclosed |
| EP-1140901-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039087-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153604-A1 | Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds | SERPINC1, F2, F11 | KDM4E 1571/4885ALDH1A1 2804/4885SMN1; SMN2 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.